NTRA raises efficiency of mobile services in Sinai with EGP 513m investment    Startups Without Borders to hold hybrid summit in Rome, Cairo    Egypt, South Korea have many cultural similarities: Korean Ambassador    Economic recovery is essential in countering COVID-19 impact on Africa: Shoukry    Egypt advances to 21st in Climate Change Performance Index 2022    UNFPA, Canada delegation visits projects in Upper Egypt    Egypt, WHO discuss mechanisms to reduce antimicrobial resistance    Plastic Bank collects 150 million bottles in 2021, equivalent to 2,700 tonnes of plastic    US awards film residency programmes to Egyptian filmmakers at CIFF 2021    Irrigation Ministry highlights threats to Egypt's water security before Senate    YouTube launches fund to reward short-form video creation in MENA region    DP World Sokhna: Integrated supply chain for Egyptian sugar    Egypt's PMI unchanged in Nov as higher inflation expectations weigh on: IHS    Egypt's LNG exports at full capacity of 1.6 bcf/d after gas price rise – minister    Indian Embassy in Cairo presents contemporary dance performances    Egypt explores water cooperation with 4 African countries    Al-Sisi visits Police Academy, witnesses admission exams    Soma Bay hosts Oceanman's Final World Championship 2021 for open-water swimming    Lebanese legend Fairuz is Egypt's most-streamed female singer on Spotify in 2021    Egypt, Qatar discuss cooperation in sports infrastructure    Mortada Mansour sets road map for Zamalek, after normalization committee depart    Egypt's trade with Nile basin countries climbs 26% y-o-y in 9 months    Egypt selected to host COP27 international climate conference in 2022    Number of British tourists to Egypt seen hitting 500,000 this winter – envoy    The unvaccinated prohibited from entry to Egypt state institutions starting December 1    Egypt, Greece ink deal for first subsea power link between Europe and Africa    SCOHRE sparks discussion on harm reduction, tobacco control    Egypt to receive first of six high-trains from Spain's Talgo in mid-November    Egypt's iron and steel exports jump 197% in 8 months    Ethiopia halts work at its embassy in Egypt for 'economic reasons'    It's a bit frustrating to draw at home: Real Madrid keeper after Villarreal game    Russia says it's in sync with US, China, Pakistan on Taliban    Shoukry reviews with Guterres Egypt's efforts to achieve SDGs, promote human rights    Sudan says countries must cooperate on vaccines    Johnson & Johnson: Second shot boosts antibodies and protection against COVID-19    Egypt to tax bloggers, YouTubers    Egypt's FM asserts importance of stability in Libya, holding elections as scheduled    Brazil calls up 8 EPL players for World Cup qualifying    We mustn't lose touch: Muller after Bayern win in Bundesliga    Egypt records 36 new deaths from Covid-19, highest since mid June    Egypt sells $3 bln US-dollar dominated eurobonds    Sisi calls on House, Senate to commence second legislative sessions on 3, 5 October    Gamal Hanafy's ceramic exhibition at Gezira Arts Centre is a must go    Italian Institute Director Davide Scalmani presents activities of the Cairo Institute for ITALIANA.IT platform    Qa'a play showing at Lycee El Horreya Theatre, Alexandria is a must go    APO Group enters new exclusive agreement with Getty Images on African press releases and images    On International Museum Day, Egypt opens two new museums at Cairo Airport    Old Cairo's Al-Fustat will be revamped on Egyptian President's directives    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Halt of coronavirus trial is "safety valve" at work: Fauci
Published in Ahram Online on 09 - 09 - 2020

The top US infectious disease expert said AstraZeneca's suspension of final testing of its COVID-19 vaccine candidate shows ``one of the safety valves'' built into the studies to spot any potential problems.
``It's unfortunate that it happened and hopefully they'll be able to proceed along with the remainder of the trial. But you don't know _ they need to investigate it further,'' Dr. Anthony Fauci, infectious diseases chief at the National Institutes of Health, told ``CBS This Morning'' on Wednesday.
Late Tuesday, AstraZeneca announced its final-stage studies are on temporary hold while the company investigates whether a research volunteer's ``potentially unexplained illness'' is a side effect of the shot or a coincidence.
Behind-the-scenes monitors known as the ``data and safety monitoring board'' in Britain paused vaccinations while alerting its safety counterparts in the US, said Dr. Moncef Slaoui of Operation Warp Speed, the Trump administration's vaccine development program.
Late last month, AstraZeneca began recruiting 30,000 people in the US for its largest study of the vaccine. It also is testing the vaccine, developed by Oxford University, in thousands of people in Britain, and in smaller studies in Brazil and South Africa.
Scientists around the world have been scrambling to develop a vaccine against the coronavirus since the pandemic began. Nearly 900,000 deaths have been reported in the pandemic.
An AstraZeneca spokesperson confirmed the pause in vaccinations covers studies in the US and other countries. The company would not provide further details of the illness.
Earlier stage studies of the vaccine hadn't revealed any serious side effects.
``It's important to point out that that's the reason why you have various phases of trials, to determine if in fact these candidates are safe,'' Fauci said. ``It's really one of the safety valves you have on clinical trials such as this.''
Nor is it uncommon for pauses in research to investigate if a reaction is really related to the vaccine or not, he said.
``I'm not concerned. I simply think is how research works and what we want research to be doing,'' said Dr. Carlos del Rio of Emory University, who isn't involved with the AstraZeneca testing, told reporters Wednesday.
Two other vaccines are in huge, final-stage tests in the United States, one made by Moderna Inc. and the other by Pfizer and Germany's BioNTech. Those two vaccines work differently than AstraZeneca's, and the studies already have recruited about two-thirds of the needed volunteers.
The development came the same day that AstraZeneca and eight other drugmakers issued an unusual pledge, vowing to uphold the highest ethical and scientific standards in developing their vaccines.
The announcement follows worries that President Donald Trump will pressure the US Food and Drug Administration to approve a vaccine before it's proven to be safe and effective.
The U.S. has invested billions of dollars in efforts to quickly develop multiple vaccines against COVID-19. But public fears that a vaccine is unsafe or ineffective could be disastrous, derailing the effort to vaccinate millions of Americans.


Clic here to read the story from its source.